JFL Life Sciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers beta lactam dry powder injections, beta lactam tablets and capsules in solid oral dosage form, oral rehydration solutions, and general tablets and capsules. It also exports its products to Africa, the Middle East, and CIS countries through merchant exporters. JFL Life Sciences Limited was incorporated in 2010 and is headquartered in Ahmedabad, India.
| Current Price | ₹10.35 |
|---|---|
| Market Cap | ₹36 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 5.3 |
| Return on Equity | 15.00% |
| 52-Week Range | ₹8.55 – ₹15.40 |
| Beta (1Y) | 0.1 |
| Dividend Yield | 0.00% |
| Revenue | ₹11 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| EPS (Basic) | ₹0.34 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Pharmaceuticals Manufacturing-100%
Jfl Life Sciences Limited is trading at ₹10.35, with a market capitalisation of ₹36 Cr.
Jfl Life Sciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Jfl Life Sciences Limited has a P/E of 5.3 and a return on equity of 15.00%.
In Q1 FY27, Jfl Life Sciences Limited reported revenue of ₹11 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.34 (standalone, parsed from the company's exchange filing).